Abstract:Abstract Background: During the COVID-19 pandemic, clinical trial recruitment cannot be carried out due to travel restrictions, transmission risks and other factors, resulting in the stagnation of a large number of ongoing or upcoming clinical trials. Objective: An intelligent screening app was developed using artificial intelligence technology to rapidly pre-screen potential patients for phase I solid tumor drug clinical trials. Methods: A total of 429 screening process records were collected from 27 phase I solid tumor drug clinical trials at the First Affiliated Hospital of Bengbu Medical College from April 2018 to May 2021. Features of the experimental data were analyzed, and the collinearity (principal component analysis) and strong correlation (χ2 test) among features were eliminated. XGBoost, Random Forest, and Naive Bayes were used to sort the weight importance of features. Finally, the pre-screening models were constructed using classification machine learning algorithm, and the optimal model was selected. Results: Among the 429 screening records, 33 were data generated by repeated subject participation in different clinical trials, and of the remaining 396 screening records, 246 (62.12%) were screened successfully. The gold standard for subject screening success is the final judgment made by the principal investigator (PI) based on the clinical trial protocol. A Venn diagram was used to identify the important feature intersections of machine learning algorithms. After intersecting the top 15 characteristic variables of different feature screening models, 9 common variables were obtained: age, sex, distance from residence to the central institution, tumor histology, tumor stage, tumorectomy, the interval from diagnosis/postoperative to screening, chemotherapy, and ECOG (Eastern Cooperative Oncology Group, ECOG) score. To select the optimal subset, the 9 important feature variables were expanded to 12 and 15 feature subsets, and the performance of different feature subsets under different machine learning models was validated. The results showed that optimal performance, accuracy and practicability were achieved using XGBoost with the 12 feature subset. The final model could accurately predict the screening success rates in both internal (AUC =3D 0.895) and external (AUC =3D 0.796) validation, and has been transformed into a convenient tool to facilitate its application in the clinical settings. Subjects with a probability exceeding or equaling to the threshold in the final model had a higher probability to be successfully screened. Conclusion: Based on the optimal model, we created an online prediction calculator and visualization app -- ISSP (Intelligent Screening Service Platform), which can rapidly screen patients for phase I solid tumor drug clinical trials. ISSP can effectively solve the problem of space and time interval. On the mobile terminal, it realizes the matching between clinical trial projects and patients, and completes the rapid screening of clinical trial subjects, so as to obtain more clinical trial subjects. As an auxiliary tool, ISSP optimizes the screening process of clinical trials and provides more convenient services for clinical investigators and patients.

Using Intelligent Screening Service Platform (ISSP) to improve the screening process of clinical trial subjects during COVID-19 pandemic: an experimental study

Development and Validation of a Risk-Prediction Model for Immune-Related Adverse Events in Patients with Non-Small-cell Lung Cancer Receiving PD-1/PD-L1 Inhibitors.

BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials

Identifying Oncology Clinical Trial Candidates Using Artificial Intelligence Predictions of Treatment Change: A Pilot Implementation Study

Analysis of the reasons for screening failure in phase I clinical trials in China: a retrospective study of the clinical trials screening process

A prospective study comparing AI-based clinical trial eligibility screening with traditional EMR-based screening.

Telehealth consultations and recruitment trends in clinical trials: A retrospective analysis at investigational cancer therapeutics, a dedicated phase I department at The University of Texas MD Anderson Cancer Center.

Artificial intelligence for optimizing recruitment and retention in clinical trials: a scoping review

Evaluating eligibility criteria of oncology trials using real-world data and AI

A self-assessment survey to identify the risk of screen failure in phase I clinical trials (SCITEP score).

Assessing the Utility of Artificial Intelligence Throughout the Triage Outpatients: a Prospective Randomized Controlled Clinical Study

Smart phone application for early detection of adverse clinical outcomes in solid malignancy.

A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy

When artificial intelligence meets PD-1/PD-L1 inhibitors: Population screening, response prediction and efficacy evaluation

Optimal Triage for COVID-19 Patients Under Limited Health Care Resources With a Parsimonious Machine Learning Prediction Model and Threshold Optimization Using Discrete-Event Simulation: Development Study

Enhancing Patient Selection in Sepsis Clinical Trials Design Through an AI Enrichment Strategy: Algorithm Development and Validation

Feasibility study utilizing a combinatorial functional precision medicine platform, Optim.AI, to help guide treatment for pancreatic cancer.

Optimizing Clinical Trial Eligibility Design Using Natural Language Processing Models and Real-World Data: Algorithm Development and Validation

Artificial intelligence tools for optimising recruitment and retention in clinical trials: a scoping review protocol

A method for intelligent allocation of diagnostic testing by leveraging data from commercial wearable devices: a case study on COVID-19

Bridging the gap: Leveraging AI to enhance access to clinical trials for underrepresented and underserved populations with cancer.